Sichuan Biokin Pharmaceutical (02615) will be issuing shares from November 7th to November 12th, and is expected to be listed on November 17th.

Sichuan Biokin Pharmaceutical (02615) will be listed from November 7th to November 12th, 2025. The company plans to globally issue 8.6343 million shares, with 10% allocated for sale in Hong Kong and 90% for international sale. There is also a 15% over-allotment option, with the offer price per share set at 347.5-389 Hong Kong dollars. Trading of the shares is expected to begin on the Hong Kong Stock Exchange on November 17th, 2025. The company is a comprehensive medical enterprise group with capabilities in early-stage research and development, clinical development, production, and commercialization. In the past performance period, the company operated two main businesses: innovative biopharmaceuticals and generic pharmaceuticals and traditional Chinese medicine. Ten years ago in 2014, the company established SystImmune in Seattle, USA, and began the development of iza-bren (BL-B01D1), which is the world's first and only EGFRHER3 bispecific antibody ADC to enter Phase III clinical development. Ten years later, the company reached a total of 8.4 billion US dollars with BMS for iza-bren, marking the largest global strategic licensing and collaboration transaction in the ADC field to date. Over the ten years of effort in the USA, the company built: (i) an innovative ADC drug development platform, successfully developing 10 innovative ADC candidate drugs including iza-bren in clinical development, conducting around 70 clinical studies, including 16 key registration clinical trials in China, 3 key registration clinical trials globally, and 16 Phase II clinical trials in first-line cancer treatment; (ii) a multi-specific T cell engager platform, successfully developing four innovative multi-specific antibody drugs pipelines including GNC-077 in clinical development and conducting 15 clinical studies; and (iii) an innovative ARC drug development platform, successfully developing the innovative ARC candidate drug BL-ARC001 approved by IND. Since 1996, after years of accumulation, the company has accumulated professional knowledge in the field of generic drugs and traditional Chinese medicine. The company's product portfolio in generic drugs and traditional Chinese medicine covers areas such as anesthesia, enteral nutrition, anti-infective, pediatrics, etc. The company has accumulated rich experiences in R&D, production, and marketing of special formulations such as emulsion injections and effervescent formulations, and has formed a competitive product portfolio. In the past performance period, the company's revenue came from sales of over 100 specifications of 31 approved drugs, including 26 generic drug products and five traditional Chinese medicine products. These products' revenue plays a crucial role in providing funds for the company's innovative drug development. The company has entered into cornerstone investment agreements with BMS, OAP III, GL Capital, Athos Capital, and Fuguofund, under certain conditions and restrictions, the cornerstone investors have agreed to subscribe at the offer price or cause their designated entities (including qualified domestic institutions approved by relevant Chinese authorities) to subscribe (as appropriate) for a total of approximately 32 million US dollars or approximately 2.49 billion Hong Kong dollars worth of shares at the offer price (adjusted to the nearest full trading unit of 100 H shares). The company estimates that after deducting underwriting commissions, expenses, and estimated expenses payable for the global offering, the net proceeds received from the global offering at an offer price of 368.25 Hong Kong dollars per share (the middle value of the indicative offer price range as described in this prospectus) will be approximately 3.018 billion Hong Kong dollars. Approximately 60.0% will be used for funding the company's bio-candidate drug R&D activities outside mainland China. Approximately 30.0% will be used to establish the company's global supply chain, mainly to fund the construction of new production facilities for the company's bio-candidate drugs outside mainland China or potential acquisition opportunities. Approximately 10.0% will be used to fund the company's operating capital and other general corporate purposes outside mainland China.